HEPARIN INDUCED THROMBOCYTOPENIA GALILA ZAHER MBB ch, dip C Path, MRC Path.

Slides:



Advertisements
Similar presentations
HEPARIN INDUCED THROMBOCYTOPENIA: HIT HAPPENS
Advertisements

Chapter 31 Antithrombotic therapy August 8, 2005.
Parenteral Anticoagulant
Anthony Worsham, MD Friday, June 18, 2010 Hospital Medicine Best Practices Meeting University of New Mexico.
Heparin-Induced Thrombocytopenia DR VINOD G V. HIT An immunoglobulin-mediated adverse drug reaction characterized by: –platelet activation –thrombocytopenia.
Heparin in CRRT Benan Bayrakci, McLean Antitrombin 3 Inactive Thrombin (IIa) V, VIII, XIII, Fibrinogen Inactive Factor Xa Common Pathway Inactive.
Prophylaxis of Venous Thromboembolism
Thrombophilia. Now considered a multicausal disease, with an interplay of acquired and genetic thrombotic risk factors Approximately half of venous thromboembolic.
Heparin-Induced Thrombocytopenia Learning Objectives
Heparin-Induced Thrombocytopenia (HIT). HIT is an immune-mediated adverse effect of heparin that paradoxically increases risk of thrombosis Heparin-Induced.
Updated 10/00medslides.com1 Heparin-Induced Thrombocytopenia Recent Advances in Management.
Potential of the Factor Xa Inhibitor Rivaroxaban for the Anticoagulation Management of Patients with Heparin-Induced Thrombocytopenia Jeanine M. Walenga,
The HITS Keep Coming Marc J. Kahn, MD, MBA, FACP Peterman-Prosser Professor Tulane University School of Medicine New Orleans, LA.
Preventing Anticoagulation Errors with Clinical Dashboards Dan Johnson, Pharm.D., BCPS August 3, 2011.
Week 7: Fibrinolysis and Thrombophilia Secondary fibrinolysis Secondary fibrinolysis Primary fibrinolysis Primary fibrinolysis Plasminogen Plasminogen.
Antiplatelet Drugs (Anti-thrombotics)
ANTICOAGULANT BY :DR ISRAA OMAR.
Anti-phospholipid syndrome Clinton Mitchell 5th year Haematology.
WARFARIN AN OVERVIEW.
Heparin-Induced Thrombocytopenia (HIT)
APPROACH TO BLEEDING DISORDERS. History of Bleeding Spontaneous vs. trauma/surgery-induced Ecchymoses without known trauma Medications or nutritional.
Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Venous Thromboembolism
Anticoagulants 1. Parenteral Anticoagulants e.g. heparin
Drugs for Coagulation disorders. There are a number of different categories of drugs which modify the coagulation process: I. Anticoagulants II. Antiplatelet.
To Clot Or Not To Clot… Emergency Care for Coagulation Disorders/Conditions Rebecca Goldsmith Pediatric Thrombosis/Hemophilia Nurse McMaster Children’s.
Protein C deficiency 25/12/2010 BY: MOHAMMED ALSAIDAN.
Tuesday Conference Approach to Thrombocytopenia Selim Krim, MD Assistant Professor TTUHSC.
 Background  Cost  Benefit  Complication.
Acute venous or arterial thrombosis Acute venous or arterial thrombosis Is there clinical concern for an anatomic compressive syndrome or occlusive iliofemoral.
Thrombophilia (Hypercoagulable States) Abdulkareem Almomen, MD Professor of Medicine & Hematology, King Saud University MED 341, Feb.2014.
Applications of bivalirudin in interventional cardiology
HEPARIN INDUCED THROMBOCYTOPENIA (HIT)
ANTIPLATELET DRUGS.
Heparin induce thrombocytopenia. Presented by the American Society of Hematology, adapted in part from the: American College of Chest Physicians Evidence-Based.
Treatment of Ischaemic Stroke The American Heart Association American Stroke Association Guidelines Stroke. 2007;38:
Fibrinolytics, anticoagulants and antiplatelets
ANTIPLATELETES AGENTS
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to to describe different classes of anti-platelet.
Drugs Susan Louw Haematology Registrar. 4 Questions to ask: Can I stop? (What is the risk of thrombosis?) Should I stop? (What is the risk of bleeding?)
Guidelines on the investigation and management of the APL syndrome Dr Wan Zaidah Abdullah BJH : (Revised of !991 guidelines by the Haemostasis.
IS IT HIT OR HAT? M&M Conference 3/28/02. HAT Mild thrombocythopenia 100K- 130K Incidence: 25% 1-4 days after starting heparin Non immune-mediated (direct.
Von Willebrand’s Disease. vWD Family of bleeding disorders Family of bleeding disorders Caused by a deficiency or an abnormality of von Willebrand Factor.
1. Normal haemostasis Haemostasis is the process whereby haemorrhage following vascular injury is arrested. It depends on closely linked interaction.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Treatment and Prevention of Heparin- Induced Thrombocytopenia Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Anticoagulant Therapy
Heparin – Lovenox - Coumadin Charnelle Lee, RN, MSN.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Drugs Used in Coagulation Disorders
The antiphospholipid syndrome (APS) is defined by two major components (see 'Classification criteria' below: 'Classification criteria' The occurrence.
Heparin-Induced Thrombocytopenia Farzaneh Dastan Assistant Professor of Pharmacotherapy, Pharm D, BCPS SBMU.
II. Antiplatelet Drugs.
Elvira Maličev Blood Transfusion Centre of Slovenia
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Warfarin Toxicity Treatment & Management
Detection of platelet- derived microparticles: An alternative strategy for the diagnosis of heparin-induced thrombocytopenia. François Mullier, N. Bailly,
Anesthes. 1998;89(6): Figure Legend:
HIT: The Consequences of Heparin’s Nonspecific Binding to Platelet Factor 4 Heparin is neutralized by platelet factor 4, (PF4), which is present in high.
Copyright © 1999 American Medical Association. All rights reserved.
Antibodies to Heparin–Platelet Factor 4 Complex: Pathogenesis, Epidemiology, and Management of Heparin-Induced Thrombocytopenia in Hemodialysis  Andrew.
Med Chem Tutoring for Anticoagulants, Antiplatelets, and Thrombolytics
Heparin induced thrombocytopenia
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with.
Antibodies to Heparin–Platelet Factor 4 Complex: Pathogenesis, Epidemiology, and Management of Heparin-Induced Thrombocytopenia in Hemodialysis  Andrew.
Thrombophilia.
The identification and management of heparin-induced thrombocytopenia in the vascular patient  Glenn M. LaMuraglia, MD, Rabih Houbballah, MD, Michael.
FIBRINOLYTIC DRUGS VIJAYA LECHIMI RAJ.
Heparin-induced thrombocytopenia
How I treat heparin-induced thrombocytopenia and thrombosis
Presentation transcript:

HEPARIN INDUCED THROMBOCYTOPENIA GALILA ZAHER MBB ch, dip C Path, MRC Path

Heparin induced thrombocytopenia(HIT) HIT: is an immune mediated side effect which can be life threatening. Incidence : 1-3%of patient receiving heparin.

Heparin induced thrombocytopenia Higher risk for HIT *Therapeutic > prophylactic doses. *Bovine lung extract > porcine heparin *Unfractunated heparin > LMWH. HIT *IV, SC, hepsal flush, extra corporal blood circuit & heparin coated materials.

Pathogenesis Heparin treatment release platelet factor 4. Heparin can bind to PF4 on platelet surface & vascular endothelium. Antibodies are directed against heparin-PF4 (H-PF4). Antibodies involved in HIT are usually IgG, but IgA & IgM have been reported.

Type 1 HIT The most common form of HIT. Early onset (3-5d). Mild thrombocytopenia(80-100x10 9 /l). Direct effect of heparin. Reversible Asymptomatic.

Type II HIT Less frequent than type I HIT Delayed onset (5-14d). Plt count is <60x10 9 /L Can be life threatening 29% mortality rate (HITT). Immunological reaction. Requires clinical intervention & immediate discontinuation of heparin.

Ice burg model: HIT-IgG HIT-IgG seroconversion 0-10% Symptomatic thrombocytopenia % Isolated thrombosis 30-80% Multiple thrombos is %

Clinical presentation of type II HIT Males and females are equally affected. All ages. Venous thrombosis more common than arterial. Patient who develop skin lesions at heparin injection sites are at increased risk of thrombosis. CVD  arterial. Post operative  venous thrombosis.

Clinical presentation *Venous thrombosis : DVT&PE. Warfarin induced venous limb gangrene. Cerebral sinus thrombosis. Adrenal hemorrhagic infarction. *Arterial thrombosis: lower limb (distal aortic or iliofemoral). Stroke & Myocardial infarction. *Acute plt activation syndrome : *Skin lesions

Laboratory diagnosis of HIT Existing lab methods do not distinguish between HIT & HITTS. * 14 C Seratonin release assay. * H-PF4 ELISA. * The platelets aggregation assay. * Flow-cytometric assay. Until improved laboratory diagnosis of HIT clinical impression are best used to direct therapy in patient with suspected HIT

Flow cytometry in diagnosis of HIT Provides rapid diagnosis. 100% specificity and sensitivity. Reproducible. flow cytometric assay of CD62P can distinguish HIT from HITTS.

Heparin therapy Regular platelets count. Type I HIT syndrome -  observation. Type II HIT syndrome : *D/C heparin *no platelet concentrate *no warfarin during the acute phase *no LMWH *Heparinoid

Thrombin inhibitors HIRUIDIN: *Natural hiruidin : The leech salivary extract (hirudo medicinalis). *synthetic hirudin (argatroban). *recombinant (r- hiruidin). Danaparoid. Hirulogs.

PLASMAPHERESIS Removal of plasma &replacement with normal plasma or colloids. It has been done on 3 consecutive days. Early treatment (4 days) reduces the incidence of mortality It dose not affect the number of the thrombotic events.

Extremity Arterial Thrombosis & Stroke. Digits only : *Argatroban. Entire extremity : *Thrombolytic therapy, *Continue argatroban, *Plasmapharesis. Stroke with no evidence of hemorrhage: *Argatroban Stroke with evidence of hemorrhage : *Plasmapheresis.

Laboratory diagnosis. ctd Combined results of the three assays enhances the positive response to 83%of the total population with HIT. The combination of the three testing with multiple samples offers the best chance of confirming a positive diagnosis of HIT. Clinical event & a positive reliable laboratory test confirms the diagnosis of HIT.

14 C serotonin release assay The gold standard for diagnosis. It is a biologic assay. It requires the use of radioactive materials. It has a sensitivity of 55%. The complexity & the slow turn around time of the assay compromise its practical usefulness for immediate treatment decisions.

THANK YOU